Results 191 to 200 of about 10,333 (209)

Treatment perspectives for human African trypanosomiasis

Fundamental & Clinical Pharmacology, 2003
AbstractHuman African trypanosomiasis (HAT), or sleeping sickness, is currently on the rise. HAT develops in two stages, the first involving the hemolymphatic system, and the second, the neurological system. Left untreated, HAT is invariably fatal. There have been no therapeutic advances in more than 40 years.
Sylvie Bisser, Michel Dumas, Bernard Bouteille, Odile Oukem   +3 more
openaire   +3 more sources

Treatment and control of human African trypanosomiasis

Current Opinion in Infectious Diseases, 2004
Access to treatment is a multi-step process and little progress has been made to improve treatments for sleeping sickness over the past 50 years. The current strategy is based on diagnostic tools developed in the 1960s while available drugs are still the same as those developed in the middle of the last century.
P Cattand, J Jannin
openaire   +3 more sources

Human African Trypanosomiasis (HAT)

2016
Human African trypanosomiasis (HAT) found only in sub-Saharan Africa is caused by the parasite Trypanosoma brucei which is transmitted by tsetse flies. Only two subspecies of T.brucei are pathogenic for humans: T.b. gambiense and T.b. rhodesiense. HAT is endemic in 36 sub-Saharan countries, and 98 % of all reported HAT cases are due to T. b. gambiense.
Pascal Lutumba, Marleen Boelaert, Enock Matovu   +2 more
openaire   +2 more sources

Eflornithine for the treatment of human African trypanosomiasis

Parasitology Research, 2003
Eflornithine is the only new molecule registered for the treatment of human African trypanosomiasis over the last 50 years. It is the drug used mainly as a back-up for melarsoprol refractory Trypanosoma brucei gambiense cases. The most commonly used dosage regimen for the treatment of T. b.
Christian Burri, Reto Brun
openaire   +3 more sources

New developments in human African trypanosomiasis

Current Opinion in Infectious Diseases, 2006
To review recent literature on human African trypanosomiasis, focussing on genome sequencing, diagnosis and drug discovery, and typing of trypanosomes.The most important recent development has been the completion of the Trypanosoma brucei genome which will greatly facilitate the discovery of new drug targets and genetic markers.
Brun, Reto, Balmer, Oliver
openaire   +4 more sources

Hormones in human African trypanosomiasis

1999
Humans suffering from African trypanosomiasis or sleeping sickness demonstrate major disruptions in their circadian sleep-wake distribution, with the intensity of the sleep-wake disturbances increasing with the stage of advancement of the disease [1]. Buguet et al. [1] postulated that the disruptions in the circadian sleep-wake cycle in infected humans
G. Brandenberger, M. W. Radomski
openaire   +2 more sources

Problems for the chemotherapy of human African trypanosomiasis

Current Opinion in Infectious Diseases, 2000
Problems associated with the current therapies of sleeping sickness include toxicity, resistance and a lack of a guaranteed supply. However, no new formulations are close to gaining a licence for clinical use and relatively few compounds have been shown to be effective in experimental systems.
openaire   +2 more sources

The nitroimidazoles and human African trypanosomiasis

1999
The arsenal of compounds available for the chemotherapy of human African trypanosomiasis (HAT) [1,2] is essentially limited to suramin and pentamidine, which are active in the hematological stage of the disease, and melarsoprol and eflornithine (DFMO) which have efficacy in the terminal (meningoencephalitic) phase.
J. Périé, G. Chauvière
openaire   +2 more sources

The epidemiology and control of human African trypanosomiasis

2001
Human African trypanosomiasis is caused by Trypanosoma brucei gambiense in West and Central Africa, and by Trypanosoma brucei rhodesiense in East and southern Africa. In recent years there has been a dramatic resurgence of Gambian trypanosomiasis in Central Africa, especially in the Democratic Republic of Congo, Angola and Sudan.
Jacques Pépin, Honore Meda
openaire   +3 more sources

Human African trypanosomiasis–neurological aspects

Journal of Neurology, 2006
Human African Trypanosomiasis (HAT),which is also known as sleeping sickness, is a major cause of death and disability in 36 countries in sub-Saharan Africa. The disease is caused by the protozoan parasite of the Trypanosoma genus which is transmitted by the bite of the tsetse fly.
openaire   +3 more sources